Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: Effects on tamoxifen-resistant MCF-7 cancer cells

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2103-2112

  Leung, Euphemia ^a   Rewcastle, Gordon W ^a   Joseph, Wayne R ^a   Rosengren, Rhonda J ^b   Larsen, Lesley ^c   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

Author keywords

Breast cancer; Camptothecin; Curcumin; Cyclohexanone; Estrogen receptor; MCF 7; Tamoxifen; Topoisomerase I

Indexed keywords

2,6 BIS(PYRIDIN 3 YLMETHYLENE)CYCLOHEXANONE; 2,6 BIS(PYRIDIN 4 YLMETHYLENE)CYCLOHEXANONE; CAMPTOTHECIN; CYCLOHEXANONE DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; HISTONE H2AX; IRINOTECAN; RL 90; RL 91; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

EID: 84875507118     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9768-4     Document Type: Article

References (27)

1. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolic L (2009) Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics 8(6):1278-1294. doi:10.1074/mcp.M800493-MCP200
2. Harris TE, Lawrence JC, Jr. (2003) TOR signaling. Sci STKE 2003 (212):re15. doi:10.1126/stke.2122003re15
3. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107(22):10208-10213. doi:10.1073/pnas.0907011107
4. Butt AJ (2011) Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer. Cancer Biol Ther 11 (11):947-949. doi:10.4161/cbt.11.11.15953
5. Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC (2010) MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9(9):717-724
6. Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC (2011) Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 11(11):938-946
7. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, Mahoney CJ, Shioda K, Isselbacher KJ, Ramaswamy S, Shioda T (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA 106 (34):14536-14541. doi:10.1073/pnas.0907560106
8. Nugoli M, Chuchana P, Vendrell J, Orsetti B, Ursule L, Nguyen C, Birnbaum D, Douzery EJ, Cohen P, Theillet C (2003) Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer 3:13. doi:10.1186/1471-2407-3-13
9. Baguley BC, Leung E (2011; in press) Heterogeneity of phenotype in breast cancer cell lines., vol Book 1. In Breast Cancer Cells. Intech Publishers
10. Somers-Edgar TJ, Taurin S, Larsen L, Chandramouli A, Nelson MA, Rosengren RJ (2009) Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs 29(1):87-97. doi:10.1007/s10637-009-9339-0
11. Shao ZM, Shen ZZ, Liu CH, Sartippour MR, Go VL, Heber D, Nguyen M (2002) Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98(2):234-240. doi:10.1002/ijc.10183
12. Markaverich BM, Schauweker TH, Gregory RR, Varma M, Kittrell FS, Medina D, Varma RS (1992) Nuclear type II sites and malignant cell proliferation: inhibition by 2, 6-bis-benzylide-necyclohexanones. Cancer Res 52(9):2482-2488
13. Reikhardt BA, Kulikova OG, Borisova GY, Aleksandrova IY, Sapronov NS (2003) Status of the "protein kinase CK2-HMG14" system in age-related amnesia in rats. Neurosci Behav Physiol 33 (8):799-804
14. Piotrovskii LB, Dumpis MA (1990) Selective alkylation of imidazole-4(5)-carboxamides. Chem Heterocycl Compd 26 (4):407-409. doi: 10.1007/bf00497210
15. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112-1116. doi:10.1038/nprot.2006.179
16. Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bonner WM, Aladjem MI, Kohn KW, Pommier Y (2006) p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene 25 (20):2839-2849. doi: 10.1038/sj.onc.1209313
17. LiuLF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1-10
18. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2(3):188-200. doi:10.1038/nrc749
19. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, Pommier Y (2001) Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 61(5):1964-1969
20. Bandyopadhyay K, Gjerset RA (2011) Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 50 (5):704-714. doi:10.1021/bi101110e
21. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592. doi:10.1146/annurev.biochem.71.102301. 093055
22. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S (2006) BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58(5):594-600. doi:10.1007/s00280-006-0212-y
23. Wu N, Wu XW, Agama K, Pommier Y, Du J, Li D, Gu LQ, Huang ZS, An LK (2010) A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells. Biochemistry 49(47):10131-10136. doi: 10.1021/bi1009419
24. Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, Riou JF (1993) Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 45(2):339-348
25. Hackbarth JS, Galvez-Peralta M, Dai NT, Loegering DA, Peterson KL, Meng XW, Karnitz LM, Kaufmann SH (2008) Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. J Biol Chem 283(24):16711-16722. doi:10.1074/jbc.M802246200
26. Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, Zhu XF (2011) PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 30(8):944-955. doi:10.1038/onc.2010.467
27. Ikeda M, Kurebayashi J, Sonoo H, Oota Y, Fujii S, Shimo T, Miyake A, Seki M, Souda M, Nomura T, Yamamoto Y, Shiiki S, Nakashima K, Tanaka K (2009) Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer. Gan To Kagaku Ryoho 36(5):773-777